Inhibrx Biosciences Inc. (NASDAQ: INBX) is a Healthcare company (Biotechnology) with a market capitalization of $1.1B. The Maz Rating grades it against the other companies in its sector.
Inhibrx Biosciences Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $74.18, Inhibrx Biosciences Inc. trades at 542.8x sales. Over the last twelve months it generated about $2M of revenue and a net loss of $134M. It runs a gross margin of 19.3%, an operating margin of -6286.7% and a net margin of -7082.9%. It shows return on equity of 373.0%, return on invested capital of -64.3% and a free cash flow yield of -12.2%. On the balance sheet: a debt-to-equity ratio of -3.28 and a current ratio of 7.58. Over the past 52 weeks the share price ranged from $57.30 to $155.29, with a beta of 4.04.
Inhibrx Biosciences Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Inhibrx Biosciences Inc. (INBX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 17.9% / 30% · (Cash+Inv) / Mkt Cap (36m) 12.9% / 30% · Interest income / Revenue 87.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 17.9% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 12.9% / 33% · Receivables / Mkt Cap (36m) 0.01% / 49% · Interest income / Revenue 87.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 17.9% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 12.9% / 33.33% · Receivables / Mkt Cap (24m) 0.01% / 33.33% · Interest income / Revenue 87.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 55.4% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 87.8% / 33.33% · Receivables / Avg Assets (4Q) 0.10% / 33.33% · Interest income / Revenue 87.6% / 5% | Fail |
| FTSE | Debt / Total Assets 125.6% / 33.33% · (Cash+ST Inv) / Total Assets 90.5% / 33.33% · (Cash+Recv) / Total Assets 90.6% / 33.33% · Interest income / Revenue 87.6% / 5% | Fail |
No. As of September 2026, Inhibrx Biosciences Inc. (INBX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Inhibrx Biosciences Inc. is over the AAOIFI limit on Interest income / Revenue.
About 87.6% of each dividend: Inhibrx Biosciences Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.